NASDAQ:BDTX Black Diamond Therapeutics (BDTX) Stock Price, News & Analysis $1.89 +0.01 (+0.53%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$1.88 -0.01 (-0.74%) As of 10/2/2026 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Black Diamond Therapeutics Stock (NASDAQ:BDTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BDTX alerts:Sign Up Key Stats Today's Range$1.88▼$1.9450-Day Range$1.66▼$2.2752-Week Range$1.60▼$4.94Volume472,186 shsAverage Volume541,168 shsMarket Capitalization$108.59 millionP/E RatioN/ADividend YieldN/APrice Target$10.25Consensus RatingModerate Buy Company Overview Black Diamond Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically defined cancers. The company uses its Mutation-Allostery-Pharmacology (MAP) platform to identify and develop “MasterKey” medicines designed to target families of oncogenic mutations, including alterations that may be difficult to address with conventional therapies. Its research and development programs have included investigational small-molecule therapies directed at cancer-driving pathways such as EGFR and RAF. The company’s drug candidates are being evaluated for potential use in solid tumors, including certain forms of non-small cell lung cancer, glioblastoma and other cancers with specific genomic alterations. Black Diamond Therapeutics was founded in 2014 and is headquartered in the United States. As a development-stage biotechnology company, it has focused primarily on research, clinical trials and advancing its oncology pipeline rather than on marketing approved commercial products. Its programs are intended to serve patients with molecularly defined cancers in markets where the relevant therapies may ultimately be approved.AI Generated. May Contain Errors. Read More Black Diamond Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreBDTX MarketRank™: Black Diamond Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 543rd out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingBlack Diamond Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on no strong buy ratings, 8 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialBlack Diamond Therapeutics has a consensus price target of $10.25, representing about 442.3% upside from its current price of $1.89.Amount of Analyst CoverageBlack Diamond Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Black Diamond Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Black Diamond Therapeutics are expected to decrease in the coming year, from ($0.57) to ($1.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Black Diamond Therapeutics is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Black Diamond Therapeutics is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBlack Diamond Therapeutics has a P/B Ratio of 0.96. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Black Diamond Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.88% of the float of Black Diamond Therapeutics has been sold short.Short Interest Ratio / Days to CoverBlack Diamond Therapeutics has a short interest ratio ("days to cover") of 10.13, which indicates bearish sentiment.Change versus previous monthShort interest in Black Diamond Therapeutics has recently decreased by 15.87%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBlack Diamond Therapeutics does not currently pay a dividend.Dividend GrowthBlack Diamond Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 2 people have searched for BDTX on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows3 people have added Black Diamond Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Black Diamond Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders9.29% of the stock of Black Diamond Therapeutics is held by insiders.Percentage Held by Institutions95.47% of the stock of Black Diamond Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Black Diamond Therapeutics' insider trading history. Receive BDTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Black Diamond Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BDTX Stock News HeadlinesBlack Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 2, 2026 | globenewswire.comStifel Nicolaus Sticks to Its Buy Rating for Black Diamond Therapeutics (BDTX)August 8, 2026 | theglobeandmail.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.October 3 at 1:00 AM | Altimetry (Ad)Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 5, 2026 | globenewswire.comBlack Diamond Therapeutics: Positive Phase 2 Results Offer An UpsideJuly 6, 2026 | seekingalpha.comBlack Diamond Shareholders Approve Directors and Annual Say-on-PayJune 30, 2026 | theglobeandmail.comWedbush Remains a Buy on Black Diamond Therapeutics (BDTX)June 4, 2026 | theglobeandmail.comBlack Diamond Therapeutics, Inc.May 24, 2026 | edition.cnn.comSee More Headlines BDTX Stock Analysis - Frequently Asked Questions How have BDTX shares performed this year? Black Diamond Therapeutics' stock was trading at $2.43 at the beginning of 2026. Since then, BDTX shares have decreased by 22.2% and is now trading at $1.89. How were Black Diamond Therapeutics' earnings last quarter? Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) posted its earnings results on Wednesday, August, 5th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.20) by $0.03. When did Black Diamond Therapeutics IPO? Black Diamond Therapeutics (BDTX) raised $180 million in an initial public offering (IPO) on Thursday, January 30th 2020. The company issued 10,586,316 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO and Canaccord Genuity was co-manager. How do I buy shares of Black Diamond Therapeutics? Shares of BDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Black Diamond Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Black Diamond Therapeutics investors own include Enovix (ENVX), Rambus (RMBS), Ginkgo Bioworks (DNA), Compass Pathways (CMPS), Toast (TOST), Meta Platforms (META) and Luminar Technologies (LAZR). Company Calendar Last Earnings8/05/2026Today10/03/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 BDTX's financial health is in the Yellow zone, according to TradeSmith. BDTX has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BDTX CIK1701541 Webwww.blackdiamondtherapeutics.com Phone(617) 417-5868FaxN/AEmployees21Year Founded2017Price Target and Rating Average Price Target for Black Diamond Therapeutics$10.25 High Price Target$14.00 Low Price Target$8.00 Potential Upside/Downside+442.3%Consensus RatingModerate Buy Rating Score (0-4)2.64 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($0.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$22.37 million Net MarginsN/A Pretax MarginN/A Return on Equity-32.10% Return on Assets-25.21% Debt Debt-to-Equity RatioN/A Current Ratio7.28 Quick Ratio7.28 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.53 per share Price / Cash Flow3.57 Book Value$1.97 per share Price / Book0.96Miscellaneous Outstanding Shares57,454,000Free Float52,117,000Market Cap$108.59 million OptionableOptionable Beta3.32 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:BDTX) was last updated on 10/3/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Black Diamond Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Black Diamond Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
